Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Common origin of human T-lymphotropic virus type-I from Iran, Kuwait, Israel, and La Reunion Island.
J Med Virol. 1997 May;52(1):77-82. Unique Identifier : AIDSLINE MED/97278127 Voevodin A; Gessain A; Department of Microbiology, Faculty of Medicine, Kuwait University,; Kuwait.
Abstract:
We found previously that Kuwaiti HTLV-I isolates had two nucleotide substitutions in the most frequently sequenced regions of HTLV-I genome, namely: T-->C 4783 in the pol and T-->C 6569 the env genes. These substitutions were observed rarely in other HTLV-I isolates and seemed to be good markers of the HTLV-I lineage, the "epicentre" of which was located in Mashhad, Iran. To test this hypothesis we sequenced the fragments of HTLV-I genome including sites 4783 and 6569 from seven isolates obtained from the Iranians either living in (five isolates) or originating from (two isolates) Mashhad. RFLP-based tests were also designed and used for typing of the substitutions. All seven isolates were positive for T-->C 4783 and six, from which env fragment was amplifiable, were also positive for T-->C 6569. It is highly probable that all the isolates from Mashhadi Jews belong to the same HTLV-I lineage, although they were not typed yet for the presence of T-->C 6569 substitution. Only 2 "non-Middle Eastern" HTLV-1, both from La Reunion Island were positive for both of the substitutions. Another possible member of Mashhadi lineage of HTLV-I is one isolate from southern India and two isolates from the American Indians, British Columbia, Canada. The determination of the T-->C 4783 and T-->C 6569 markers in HTLV-I isolates of different geographical/ethnic origin may be useful for the reconstruction of the routes of HTLV-I spread from the Middle East and/or Indian subcontinent to other regions of the world and, possibly, for gaining insights into the origin of HTLV-I in Asia.
Keywords: *HTLV-I/CHEMISTRY *HTLV-I/GENETICS *HTLV-I Infections/EPIDEMIOLOGY *HTLV-I Infections/GENETICS 970930
M9791316
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
